| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | BRTX-100 (autologous hypoxically cultured mesenchymal stem cell therapy) chronic lumbar disc disease (cLDD) | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System | |
phase 2 data readout example | BRTX-100 (autologous hypoxically cultured mesenchymal stem cell therapy) chronic lumbar disc disease (cLDD) | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System | |
phase 2 data readout example | BRTX-100 (autologous hypoxically cultured mesenchymal stem cell therapy) chronic lumbar disc disease (cLDD) | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System |
Recent Updates
Recently added Catalysts
BioRestorative Therapies, Inc.$0.35
0 (-1.31%)
D 20Pipeline Score Richly Valued Biotech · Clinical
Market Cap
5.30 M
EPS
-1.12
P/E Ratio
-
Value Trade
548.43 K
SEC Financials
Q1 2026Dilution Risk
Revenue
23.17 K
R&D Expenses
1.93 M
Operating CF
-3.81 M
Total Assets
4.64 M
Total Liabilities
4.64 M
Equity
3.03 M
D/E Ratio
12,345
9.47 %
Week
-15.79 %
1 Month
-19.69 %
3 Month
-81.09 %
6 Month
-99.37 %
5 Year
-100 %
All Time
Cash Data
Cash Position
3.59 M
Monthly Burn
1.27 M
Runway
1.1 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
195.06 K
52 Week Range
0.16 - 2.05
% held by Insiders
8.5 %
% held by Institutions
7.19 %
Enterprise Value
1.74 M
Total Shares
25.48 M
Short %
4.4 %
Float Shares
25.10 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D20
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 18%
Micro Cap (rank 748 of 911)
Percentile RankBioRestorative Therapies, Inc. faces pipeline headwinds (20/100), with $223M risk-adjusted pipeline value, led by BRTX-100 in Lumbar Disc Disease (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRTX-100 Monoclonal antibody | Lumbar Disc Disease | Phase 2 | NCT04042844 | 21% | $223M | RECRUITING | 99 | STALLED | C (58) | Dec 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BRTX-100 Fast Track | chronic lumbar disc disease | Phase 2 | 2026-05-07 | 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures Read More | BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease Read More | |
BRTX-100 Fast Track | chronic lumbar disc disease | Phase 2 | 2026-05-07 | 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures Read More | BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease Read More | |
BRTX-100 Fast Track | chronic lumbar disc disease | Phase 2 | 2026-05-07 | 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures Read More | BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BRTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BRTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How BRTX ranks across every disease it competes inCompetitive Position is a premium feature
See how BRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial